Furestem-RA is under clinical development by Kangstem Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Furestem-RA’s likelihood of approval (LoA) and phase transition for Rheumatoid Arthritis took place on 17 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Furestem-RA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Furestem-RA overview

Furestem-RA is under development for the treatment of rheumatoid arthritis and Coronavirus Disease 2019 (COVID-19) associated acute respiratory distress syndrome. It is a stem cell therapy administered through intravenous route. It consists of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) derived from immature new born cells.

Kangstem Biotech overview

Kangstem Biotech is a biopharmaceutical company that develops stem cell therapeutic products for the treatment of incurable diseases using umbilical cord blood-derived stem cells. The company’s stem cell therapy products include Furestem-AD for treating subacute and chronic atopic dermatitis; Furestem-RA for treating rheumatoid arthritis; and Furestem-CD for treating active Crohn’s disease. It offers umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors. Kang Stem Biotech also provides stem cell culture media comprising KSB-3 kit, a medium for culturing the human mesenchymal stem cell. The company has operations in Seoul and Gwangmyeong, South Korea. Kangstem Biotech is headquartered in Seoul, South Korea.

Quick View Furestem-RA LOA Data

Report Segments
  • Innovator
Drug Name
  • Furestem-RA
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.